Digital Trials Digest, our quarterly newsletter
AI, patient advocacy groups, digital health technologies, and more. Here’s everything you need to know about the clinical trial trends of 2024—and how they’re reshaping the industry.
The FDA’s PFDD guidance series is a much-needed update to the PRO guidance released in 2009. But, what do these new recommendations mean for electronic data capture in clinical trials? Here’s what you need to know.
Artificial intelligence (AI) is transforming the landscape of patient engagement in clinical trials. Here’s everything you need to know.
Virtual clinical trials (VCTs) are a transformative approach to clinical research that's gaining momentum in the life sciences industry.
ePROs, or electronic patient-reported outcomes, play an essential role in clinical trials, illuminating patients' lived experiences.
Renovia needed a solution to evaluate the efficacy of its leva® Pelvic Health System for treating urinary incontinence, while ensuring ease of use for a busy female population. Of particular importance was enabling real-time symptom tracking and maintaining high patient engagement—without requiring in-person site visits.
In a recent study, we found that caregivers both underreported and overreported certain stool consistencies compared to clinician ratings. We need to make it easier for parents to report in clinical trials. See why digital image capture is an improved method for assessments of treatment efficacy and health status for pediatric GI research.
In the second of our two-part series, we explore how integrating mobile technology into study design can help attract and retain minorities and women as trial subjects.
With travel hampered and clinical trials disrupted, it’s difficult to conduct on-site clinical trial monitoring. The alternative — remote monitoring — has always made sense, but now this cost-effective, time-saving model is rightfully gaining steam. Remote monitoring in clinical trials means monitors don’t visit the site to transfer and review the data. Instead, the data monitoring is done virtually. With the use of digital technology, CROs and study sponsors/stakeholders can see the data from wherever they are located.
DCTs offer an effective avenue for studying what are sometimes considered “taboo” therapeutic areas while respecting participants’ discretion.